I'll just jump in really fast here.
I would say, in response to the statement that CEPA is fine and that it doesn't need rewording but that we just need to use it, I wouldn't agree with that entirely. As a framework law, there is a lot you can do with it, but there are certain sections and language in it that, in a clause-by-clause review, we would say need to be strengthened. These would include expanding the scope of CEPA toxic scheduled items to address things like developmental toxins and, in particular, classified human carcinogens, which it doesn't do, as Mr. Moffet noted. So that's there.
If we are talking about definitions, once you put in the words “cost-effective”, I think we would argue that you have to address it more broadly, the way the commission did in Europe, which is that cost-effective does not simply pertain to economic terms. What are the real costs of these cancer deaths, or these people who feel trespassed because they're concerned about their reproductive health or are concerned about early puberty in kids, or whatever? Those are costs too, and they certainly are public costs and political costs. So these things have to be looked at.
One point on REACH is that it's true that REACH is a work in progress, but there are a number of directives that have been adopted by all those countries in the EU, which have already addressed a number of the issues we're saying should be addressed in a renewed CEPA. So whether REACH gets more or less diluted, or whether it's passed by the European Parliament or not, there are a half a dozen directives that have been in place, some of them for a couple of decades, that address the fact that there should not be certain classes of compounds allowed in consumer products, that certain emissions will not be allowed, that there be national registries of those who emit certain carcinogens, and so on. So REACH seeks to consolidate a lot of that work that has already happened there.